Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vapourtec Keeps it Cool with Patented Cooled Reactor System

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
The patented Cooled Reactor system, developed by Vapourtec and launched in 2010, is continuing to play a key role in major flow chemistry research breakthroughs.

Recently cited in an important research paper “Continuous flow-processing of organometallic reagents using an advanced peristaltic pumping system and the telescoped flow synthesis of (E/Z)-Tamoxifen” by the Group of Prof Steven V. Ley, Department of Chemistry, University of Cambridge (UK),  the system contributes to a more efficient manufacturing process for Breast Cancer drug Tamoxifen. 

The system, which offers the ability to run continuous cryogenic reaction conditions down to -70C without the need to use expensive chillers and external devices, is currently used in laboratories around the world in conjunction with Vapourtec’s industry leading E-Series and R-Series flow chemistry systems.

Andrew Mansfield of Vapourtec commented: “The Cooled Reactor system utilises a dry ice heat exchanger to generate a chilled gas supply that cools the reactor down to the required temperature.

“A total of 110 research laboratories across the globe are currently using our patented Cooled Reactor system to maintain temperature consistency during flow chemistry experiments.

“It’s a ground breaking addition to our existing R-Series and E-Series flow chemistry systems that, three years after its introduction, is contributing to some of the most exciting chemistry research developments,” added Andrew.  

Founded in 2003, Vapourtec is established as one of the leading global manufacturers of flow chemistry systems for a wide range of industries across the world including education and pharmaceuticals. The company currently employs 12 people in Bury St Edmunds (UK) and Kuala Lumpur (Malaysia) and has received over 100 citations within peer review publications, significantly more than anyone else in their market.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos